Abstracts tagged "Fever and pediatric rheumatology"

Abstract Number: 1453 • 2015 ACR/ARHP Annual Meeting
Surveillance of Periodic Fever Syndromes in Canada
Paul Dancey^1,2, Susanne Benseler³, Marco Gattorno⁴, Anne K Junker⁵, Ronald Laxer⁶, Paivi Miettunen⁷ and Lesley Ann Turner⁸, ¹Health Science Centre, Memorial University of Newfoundland, St Johns, NF, Canada, ²Pediatrics, Janeway Children's Hospital, St. John's, NF, Canada, ³Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ⁴Pediatry, G. Gaslini Institute, Genova, Italy, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Memorial University, St. John's, NF, Canada
Background/Purpose: To estimate the incidence of periodic fever syndromes in the Canadian paediatric population, to describe the patterns of presentation, and to raise awareness in…
Abstract Number: 2003 • 2012 ACR/ARHP Annual Meeting
Colchicine As a Therapeutic Option in Periodic Fever Aphtous Stomatitis, Pharingitis Syndrome. and Cervical Adenitis (PFAPA)
Yonatan butbul Aviel¹, Sameh Tatour², Ruth Gershoni³ and Riva Brik⁴, ¹Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel, ²Pediatric Unit B, Rambam Medical Center, Israel, ³Genetics Unit, Rambam, Israel, ⁴Pediatric Unit B, Rambam Medical center
Background/Purpose: PFAPA syndrome is episodic disease characterized by periodic episodes of high fever, aphthous stomatitis, pharyngitis, and cervical adenitis, so far no therapy was shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].